PMID- 27667797
OWN - NLM
STAT- MEDLINE
DCOM- 20170926
LR  - 20221207
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 33
IP  - 3
DP  - 2017 Mar
TI  - Glycemic control and safety in Chinese patients with type 2 diabetes mellitus who 
      switched from premixed insulin to insulin glargine plus oral antidiabetics: a 
      large, prospective, observational study.
LID - 10.1002/dmrr.2863 [doi]
AB  - In some circumstances, the premixed insulin should be switched to alternative 
      therapy. The effectiveness and the safety of switching from premixed insulin to 
      insulin glargine plus oral antidiabetic drugs (OADs) in Chinese patients with 
      type 2 diabetes mellitus (T2DM) have not been clarified and, hence, will be 
      assessed in this study. Chinese patients with T2DM (2013 men and women aged 
      18-75 years) who had received premixed insulin +/- OADs for >/=3 months with glycated 
      hemoglobin (HbA1c) </= 10% were enrolled in a prospective, observational study 
      conducted at 53 hospitals across China. At baseline and at the discretion of the 
      physician, patients switched from premixed insulin to insulin glargine plus OADs. 
      Changes in HbA1c, fasting plasma glucose (FPG), 2-hour postprandial glucose 
      (PPG), treatment satisfaction, and the incidence of hypoglycemia were assessed 
      for 16 weeks. In total, 1850 patients completed the study. Mean HbA1c level for 
      the group decreased significantly (from 7.8% +/- 1.2% at week 1 to 7.0% +/- 1.0% at 
      week 16; P < .0001), and 55.2% of patients achieved HbA1c < 7% at week 16. Mean 
      FPG and 2-hour PPG decreased significantly (-1.4 +/- 2.2 and -2.1 +/- 3.9 mmol/L, 
      respectively; both P < .0001), whereas patient satisfaction improved 
      significantly. Adverse events were reported in 18.7% of patients. Chinese 
      patients with T2DM who switched from premixed insulin to insulin glargine plus 
      OADs achieved significantly improved glycemic control and treatment satisfaction 
      with a low incidence of hypoglycemia. Patients who are most likely to achieve the 
      HbA1c target less than 7% are younger, have shorter disease duration, and have 
      lower baseline HbA1c and FPG levels.
CI  - Copyright (c) 2016 John Wiley & Sons, Ltd.
FAU - Zhang, Bo
AU  - Zhang B
AD  - Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
FAU - Zhao, Jing
AU  - Zhao J
AD  - Sanofi (China) Investment Co, Ltd, Shanghai, China.
FAU - Yang, Wenying
AU  - Yang W
AD  - Department of Endocrinology, China-Japan Friendship Hospital, Beijing, China.
CN  - Lantus Registry Study Group
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20161108
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Insulin, Long-Acting)
RN  - 0 (hemoglobin A1c protein, human)
RN  - 2ZM8CX04RZ (Insulin Glargine)
SB  - IM
MH  - Administration, Oral
MH  - Biomarkers/analysis
MH  - Blood Glucose/analysis
MH  - China
MH  - Diabetes Mellitus, Type 2/*drug therapy
MH  - Drug Therapy, Combination
MH  - Female
MH  - Follow-Up Studies
MH  - Glycated Hemoglobin/analysis
MH  - Humans
MH  - Hyperglycemia/*prevention & control
MH  - Hypoglycemia/*prevention & control
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Insulin Glargine/*therapeutic use
MH  - Insulin, Long-Acting/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Postprandial Period
MH  - Prospective Studies
MH  - Treatment Outcome
OTO - NOTNLM
OT  - glycemic control
OT  - hypoglycemia
OT  - insulin glargine
OT  - premixed insulin
OT  - type 2 diabetes mellitus
EDAT- 2016/09/27 06:00
MHDA- 2017/09/28 06:00
CRDT- 2016/09/27 06:00
PHST- 2015/11/06 00:00 [received]
PHST- 2016/05/27 00:00 [revised]
PHST- 2016/08/29 00:00 [accepted]
PHST- 2016/09/27 06:00 [pubmed]
PHST- 2017/09/28 06:00 [medline]
PHST- 2016/09/27 06:00 [entrez]
AID - 10.1002/dmrr.2863 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2017 Mar;33(3). doi: 10.1002/dmrr.2863. Epub 2016 Nov 8.